Women with axial spondyloarthritis are less likely than men to respond to multiple different classes of advanced therapies, ...

Clinical improvements were achieved and maintained for up to 3 years among bDMARD-naïve patients with PsA who received bimekizumab.

MoonLake Immunotherapeutics shares surged 31% after the Financial Times reported, citing unnamed sources, that the company had rejected an initial acquisition offer by Merck & Co. for more than $3 ...

IL-17A and IL-17F affect the pathogenesis of Crohn's disease and ulcerative colitis, although their precise role in the development of these disorders requires further characterization.

Belgian drugmaker UCB (Euronext: UCB) today announced new three-year data from Phase III trials, and their open-label ...

Alongside the data in PsA, UCB will present at EULAR new results demonstrating that Bimzelx delivered sustained clinical ...

UCB puts the performance of its drug down to its ability to inhibit both IL-17A and IL-17F, while Cosentyx only targets IL-17A . It says there is evidence to suggest that IL-17F is also a key ...

The Malta International Arts Festival returns June 13–22 with music, dance, theatre, and visual art performances across ...

PLAYBOOK Q&A: Charles Isbell Jr., who was approved Monday as the next chancellor of the University of Illinois Urbana-Champaign and vice president of the University of Illinois System, comes into ...

Like everywhere else, the cost of car insurance in Illinois has gone up: Annual full coverage premiums in the state averaged about $2,436 in 2025, or $203 a month. For minimum coverage ...